Bioscience Ventures Ltd
Bioscience Ventures Ltd is a joint venture between the University of Birmingham and Abingdon Health Limited - formed in November 2010
Key Business: Developing new diagnostic tools for conditions where there is currently unmet need in markets such as oncology, genetic diseases and platform technologies with applications in many areas including infectious diseases, drug testing and veterinary.
Alta Bioscience Ltd
Manufactures and sells specialty chemicals such as peptides and oligonucleotides and performs amino-acid analysis and protein sequencing for the pharmaceutical industry, food industry and academia.
Specialist cancer diagnostic company, set up to improve patient management through better diagnostic and prognostic assessment of patients with myeloma and other plasma cell disorders. Point of care (near-patient) testing for more timely therapeutic intervention. Also supply a broad range of class and subclass specific anti immunoglobulin antibodies.
Linear Diagnostics Ltd
Focused on the development of a platform technology based on linear dichroism which is currently being applied to the multiplexed detection of infectious disease agents in sepsis.
A merger of Hybrid Biosystems (Professor Len Seymour - Division of Cancer Studies, 1997) and Myotec Therapeutics in December 2010.
Key Business: Development of non-traditional therapeutics for serious diseases. The company's approach is to combine different elements including small molecules, viruses, polymers and other macro-molecules to produce novel patent protected therapeutics. It deliberately targets diseases that result in significant associated global morbidity and mortality, with a particular focus upon cancer.
The Native Antigen Company
A spin-out of Hybrid Biosystems (Professor Len Seymour - Division of Cancer Studies, 1997) in November 2010
Specialises in the purification of native viral and bacterial antigens for in vitro diagnostics manufacturers. The scientific team, based in Oxford, has the scope to produce almost any native antigen, from small to bulk quantity. In addition, it offers an adenovirus purification capability and a screening service for anti-cancer drug compounds.
Founded by Professor Nicholas Barnes (Division of Neuropharmacology) in 2004, Celentyx's core technology is in-vitro screens for prediction of drug candidates on theimmune system.
Key business is a contract service for pharma/biotech re lead candidate prioritisation and toxicity evaluation.
Founded by Professor Ann Logan (Division of Neuropharmacology) in 2005. The core technology is siRNA-based drugs to enhance neuron survival and nerve regeneration.
Key business is consultancy and a neural tissue/cell analysis service for screening neuropharmaceuticals in the nerve regeneration and neural repair arena.
Founded by Professor Roy Bicknell and Dr Nagy in 2004 (University of Oxford – now University of Birmingham) in 2004
Core Technology: Cell cycle-related biomarkers associated with the risk of developing Alzheimer’s disease (AD).
Key Business: Developing products and services for neurodegenerative disorders such as Alzheimer's disease
Founded by Imperial/Oxford acquired anti-rejection technology from University of Birmingham in 2007.
Core Technology: Administration of carefully selected sections of molecules that cause allergic reactions to shut down patients’ over sensitive immune responses, and thereby desensitise sufferers.
Key Business: Biopharmaceutical company focused on developing a new class of T-cell vaccines designed to treat allergies and combat organ transplant rejection.
Founded by Professor Richard Palmer (Physics) in 2005
Core Technology: Nano-scale surface fabrication technology .
Key Business: Developing a low cost, accessible (point-of-care) diagnostic platform for the early detection and monitoring of cancer.
Founded by Professor Richard Palmer (Physics), Professor Jon Preece (Chemistry) and Dr Alex Robinson (Chemical Engineering), Irresistable Materials was established as a spinout company in 2011 (Inc 2009).
Core Technology: Novel fullerene materials.
Key Business: Developing resist materials to enable semiconductor industry to utilise EUV lithography.
Founded by Professor Tim Button (Functional Materials Group) in 2002
Core Technology: Novel ceramic processing technologies which enable the manufacture of unique functional ceramic devices in complex shapes and microscale sizes.
Key Business: Developing high frequency transducers, primarily for ultrasonic medical imaging.
Founded by Professor Lynne Macaskie (Biosciences) in 2008
Core Technology: New process to convert biological waste into hydrogen
Key Business: Developing and commercialising process systems which increase the energy recoverable from biowaste streams.
Founded in 1995.
Key Business: Conceives, develops and pioneers innovative actuation solutions for consumer electronics
Metal Nanopowders Ltd
Founded by Dr Isaac Chang (Metallurgy and Materials) in 2002
Core Technology: Novel process for production of metals and metal compounds at nano-scale.
Key Business: Production of metal–based materials at the sub-100nm scale with exceptional purity & physical properties.